PMID- 27935017
OWN - NLM
STAT- MEDLINE
DCOM- 20180326
LR  - 20220316
IS  - 1600-0404 (Electronic)
IS  - 0001-6314 (Linking)
VI  - 136
IP  - 3
DP  - 2017 Sep
TI  - EARLY-ESLI study: Long-term experience with eslicarbazepine acetate after first 
      monotherapy failure.
PG  - 254-264
LID - 10.1111/ane.12720 [doi]
AB  - PURPOSE: Evaluate real-life experience with eslicarbazepine acetate (ESL) after 
      first monotherapy failure in a large series of patients with focal epilepsy. 
      METHOD: Multicentre, retrospective, 1-year, observational study in patients older 
      than 18 years, with focal epilepsy, who had failed first antiepileptic drug 
      monotherapy and who received ESL. Data from clinical records were analysed at 
      baseline, 3, 6 and 12 months to assess effectiveness and tolerability. RESULTS: 
      Eslicarbazepine acetate was initiated in 253 patients. The 1-year retention rate 
      was 92.9%, and the final median dose of ESL was 800 mg. At 12 months, 62.3% of 
      patients had been seizure free for 6 months; 37.3% had been seizure free for 
      1 year. During follow-up, 31.6% of the patients reported ESL-related adverse 
      events (AEs), most commonly somnolence (8.7%) and dizziness (5.1%), and 3.6% 
      discontinued due to AEs. Hyponatraemia was observed in seven patients (2.8%). 
      After starting ESL, 137 patients (54.2%) withdrew the prior monotherapy and 
      converted to ESL monotherapy; 75.9% were seizure free, 87.6% were responders, 
      4.4% worsened, and 23.4% reported ESL-related AEs. CONCLUSION: Use of ESL after 
      first monotherapy failure was associated with an optimal seizure control and 
      tolerability profile. Over half of patients were converted to ESL monotherapy 
      during follow-up.
CI  - (c) 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Villanueva, V
AU  - Villanueva V
AD  - Hospital Universitario y Politecnico La Fe, Valencia, Spain.
FAU - Bermejo, P
AU  - Bermejo P
AD  - Hospital Universitario Puerta Hierro, Madrid, Spain.
FAU - Montoya, J
AU  - Montoya J
AD  - Hospital Lluis Alcanyis, Xativa, Spain.
FAU - Toledo, M
AU  - Toledo M
AD  - Hospital Universitario Vall d'Hebron, Barcelona, Spain.
FAU - Gomez-Ibanez, A
AU  - Gomez-Ibanez A
AD  - Hospital Universitario y Politecnico La Fe, Valencia, Spain.
FAU - Garces, M
AU  - Garces M
AD  - Hospital Universitario y Politecnico La Fe, Valencia, Spain.
FAU - Vilella, L
AU  - Vilella L
AD  - Hospital Universitario Vall d'Hebron, Barcelona, Spain.
FAU - Lopez-Gonzalez, F J
AU  - Lopez-Gonzalez FJ
AD  - Hospital Clinico Universitario, Santiago, Spain.
FAU - Rodriguez-Osorio, X
AU  - Rodriguez-Osorio X
AD  - Hospital Clinico Universitario, Santiago, Spain.
FAU - Campos, D
AU  - Campos D
AD  - Hospital Clinico Universitario, Valladolid, Spain.
FAU - Martinez, P
AU  - Martinez P
AD  - Hospital Universitario Virgen del Rocio, Sevilla, Spain.
FAU - Giner, P
AU  - Giner P
AD  - Hospital Universitario Dr. Peset, Valencia, Spain.
FAU - Zurita, J
AU  - Zurita J
AD  - Hospital Universitario Infanta Leonor, Madrid, Spain.
FAU - Rodriguez-Uranga, J
AU  - Rodriguez-Uranga J
AD  - Clinica Sagrado Corazon, Instituto de Especialidades Neurologicas, Sevilla, 
      Spain.
FAU - Ojeda, J
AU  - Ojeda J
AD  - Hospital Universitario Infanta Sofia, Madrid, Spain.
FAU - Mauri, J A
AU  - Mauri JA
AD  - Hospital Clinico Universitario Lozano Blesa, Zaragoza, Spain.
FAU - Camacho, J L
AU  - Camacho JL
AD  - Hospital Clinico Universitario Lozano Blesa, Zaragoza, Spain.
FAU - Ruiz-Gimenez, J
AU  - Ruiz-Gimenez J
AD  - Hospital Universitario Virgen de las Nieves, Granada, Spain.
FAU - Poza, J J
AU  - Poza JJ
AD  - Hospital Universitario Donosti, San Sebastian, Spain.
FAU - Massot-Tarrus, A
AU  - Massot-Tarrus A
AD  - Hospital Universitario Gregorio Maranon, Madrid, Spain.
FAU - Galiano, M L
AU  - Galiano ML
AD  - Hospital Universitario Gregorio Maranon, Madrid, Spain.
FAU - Bonet, M
AU  - Bonet M
AD  - Hospital Arnau de Vilanova, Valencia, Spain.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
DEP - 20161209
PL  - Denmark
TA  - Acta Neurol Scand
JT  - Acta neurologica Scandinavica
JID - 0370336
RN  - 0 (Anticonvulsants)
RN  - 0 (Dibenzazepines)
RN  - BEA68ZVB2K (eslicarbazepine acetate)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anticonvulsants/administration & dosage/*adverse effects/therapeutic use
MH  - Dibenzazepines/administration & dosage/*adverse effects/therapeutic use
MH  - Dizziness/*etiology
MH  - Epilepsies, Partial/*drug therapy
MH  - Female
MH  - Humans
MH  - Hyponatremia/*etiology
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Vertigo/*etiology
OTO - NOTNLM
OT  - epilepsy
OT  - focal seizures
OT  - partial seizures
OT  - real-life
OT  - retrospective
OT  - sodium channel
EDAT- 2016/12/10 06:00
MHDA- 2018/03/27 06:00
CRDT- 2016/12/10 06:00
PHST- 2016/11/17 00:00 [accepted]
PHST- 2016/12/10 06:00 [pubmed]
PHST- 2018/03/27 06:00 [medline]
PHST- 2016/12/10 06:00 [entrez]
AID - 10.1111/ane.12720 [doi]
PST - ppublish
SO  - Acta Neurol Scand. 2017 Sep;136(3):254-264. doi: 10.1111/ane.12720. Epub 2016 Dec 
      9.